NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Form 8-K — Aug 13, 2026
NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026, with product revenue up 16% year over year to $2.0 million, product gross margin reaching a record 59.9%, and gross profit up 29% to $1.2 million. Demand outpaced shipments: the company booked $2.7 million of new product orders during the quarter (up 43% year over year), building backlog to $1.7 million, and has received $11.2 million of orders for fiscal 2026 with recognized revenue expected between $9.2 million and $10.5 million.
Key figures
- Eps
- -0.23 basic / -0.28 diluted
- Revenue
- 1973105
- Guidance
- FY2026 recognized revenue expected to range from $9.2 million to $10.5 million depending on manufacturing completion and shipment timing
- Revenue Yoy
- 16%
- Total Assets
- 6186095
- Cash Position
- 2047596
- Shares Outstanding
- 8702982
- Backlog
- $1.7 million
- Rd Expenses
- 1425153
- Sga Expenses
- 2181768
- Reverse Split
- 1-for-6, began trading split-adjusted April 16, 2026
- Atm Raised In Q3
- $0.4 million
- Working Capital
- $3.7 million
- Debt Outstanding
- 0
- Orders Growth Yoy
- 43%
- Q3 Product Orders
- $2.7 million
- Prior Year Q3 Revenue
- 1696050
- Product Gross Margin
- 59.9%
- Product Gross Profit
- 1182609
- Atm Post Quarter Raise
- $1.0 million via 400,346 shares on July 13, 2026
- Fy2026 Product Orders
- $11.2 million
- Prior Year Gross Margin
- 53.9%
- Total Operating Expenses
- 3606921
- Lead Investor Stake Change
- 7.4% to 12.5% post-quarter
- Atm Cumulative Gross Proceeds
- $8.4 million
Price after filing
Close on the filing date to close N calendar days later (from $1.83). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.